Replies to post #108490 on Biotech Values

[DewDiligence]

I'm beginning to wonder whether the objective here is to try to push FDA into approving other Lovenox generics, or whether they are trying to put FDA into a defensive position when reviewing other MNTA applications (i.e. Copaxone).

The latter, IMO. The importance of Copaxone to Teva’s top and bottom lines is hard to overestimate. If the FDA approves NVS/MNTA’s generic Copaxone in the next year or two, Teva will not be able to meet its publicly stated goals for 2015 that were served up to Wall Street with much fanfare in January (#msg-45249487).